Q1 26 EPS
$2.65
Q1 26 Revenue
$15.00B
BEAT +1.93%
Est. $14.72B
vs S&P Since Q1 26
+3.1%
BEATING MARKET
ABBV +4.3% vs S&P +1.3%
Market Reaction
Did ABBV Beat Earnings? Q1 2026 Results
AbbVie posted a mixed but broadly constructive first quarter for 2026, delivering revenue of $15.00 billion, up 12.4% year over year and ahead of the $14.72 billion consensus, while adjusted diluted EPS of $2.65 came in just shy of the $2.67 analyst … Read more AbbVie posted a mixed but broadly constructive first quarter for 2026, delivering revenue of $15.00 billion, up 12.4% year over year and ahead of the $14.72 billion consensus, while adjusted diluted EPS of $2.65 came in just shy of the $2.67 analyst estimate, a miss of 0.66%. The earnings shortfall was largely explained by a $744.00 million pre-tax charge tied to acquired in-process research and development and milestones, which shaved $0.41 per share from adjusted results. The immunology franchise carried the quarter, generating $7.29 billion in segment revenue, with Skyrizi climbing 30.9% to $4.48 billion and Rinvoq rising 23.3% to $2.12 billion, more than compensating for Humira's continued erosion to $688.00 million. Neuroscience added further momentum, growing 26.0% to $2.88 billion. Encouraged by the quarter's performance, AbbVie raised its full-year 2026 adjusted EPS guidance to $14.08 to $14.28, from the prior range of $13.96 to $14.16, signaling management's confidence that Skyrizi and Rinvoq can sustain the growth trajectory through the rest of the year.
Key Takeaways
- • Skyrizi net revenues grew 30.9% to $4.483 billion, driven by strong U.S. growth of 29.3% and international growth of 39.8%
- • Rinvoq net revenues grew 23.3% to $2.119 billion with broad-based demand
- • Neuroscience portfolio up 26.0% with strong contributions from Botox Therapeutic, Vraylar, and the migraine franchise
- • Botox Cosmetic grew 20.2%, driving aesthetics portfolio improvement
- • Qulipta and Ubrelvy combined grew significantly with 53.6% and 41.4% increases respectively
- • Vyalev reached $201 million in quarterly revenue
ABBV Forward Guidance & Outlook
AbbVie raised its full-year 2026 adjusted diluted EPS guidance to $14.08–$14.28, up from the prior range of $13.96–$14.16. This updated guidance includes an unfavorable impact of $0.41 per share related to acquired IPR&D and milestones expense incurred year-to-date through Q1 2026. The guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond Q1 2026, as both cannot be reliably forecasted.
ABBV YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
ABBV Revenue by Segment
With YoY comparisons, source: SEC Filings
ABBV Revenue by Geography
With YoY comparisons, source: SEC Filings
“We are off to an excellent start in 2026, with first-quarter results exceeding our expectations. AbbVie's key growth drivers continue to deliver strong performance and support our enhanced full-year outlook.”
— Robert A. Michael, Q1 2026 Earnings Press Release
ABBV Earnings Trends
ABBV vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ABBV EPS Trend
Earnings per share: estimate vs actual
ABBV Revenue Trend
Quarterly revenue: estimate vs actual
ABBV Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $2.65 | — | $15.00B | +1.93% |
| Q4 25 MISS FY | $3.35 | $2.71 | -19.10% | $16.62B | +1.22% |
| FY Full Year | $9.94 | $10.00 | +0.64% | $61.16B | +0.33% |
| Q3 25 BEAT | $1.78 | $1.86 | +4.23% | $15.78B | +1.23% |
| Q2 25 BEAT | $2.91 | $2.97 | +2.14% | $15.42B | +2.61% |
| Q1 25 BEAT | $2.40 | $2.46 | +2.62% | $13.34B | +3.27% |